Fig. 5
From: Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β
The CLDN4 signaling targets LXRβS432 in breast cancer cells. A Western blot analysis showing the absence of LXRβ protein in T47D:CLDN4–/–:LXRβ–/– cells. B Western blot analysis for the indicated proteins in the revealed T47D cells. C, F Quantitative BrdU assay for the indicated cells. The BrdU/DAPI levels are plotted and shown in the histograms (mean ± SD; n = 4 for C; n = 6 for F). 30 min (C) and 60 min (F) indicate exposure time for BrdU labeling. dKO, CLDN4–/–:LXRβ –/–. D, E, G, H The intracellular cholesterol (D, G) and triglyceride (E, H) levels in the indicated T47D cells are plotted and shown in histograms (mean ± SD; n = 5). I Gross appearance and weight of the indicated xenografts at 28 days after the inoculation. The tumor weight is plotted and shown in histograms (mean ± SD; n = 5). Similar results were obtained from xenograft experiments using different clones. Scale bar, 1 cm. J Association of either AKT or SGK1 and LXRβ in 293T cells transiently transfected with the HA-LXRβ -WT or HA-LXRβ -S432A expression vector. In the input lanes, 0.1% of the input protein samples were loaded. IP, immunoprecipitation; IB, immunoblot